Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
Date:3/11/2009

ide of Italy;
  • The European Medicines Agency (EMEA) granted Premacure AB orphan designation for Insmed's IPLEX(TM) for the prevention of retinopathy of prematurity (ROP) in neonates of less than 32 weeks of gestational age. Premacure AB intends to initiate a phase 2 multicenter trial for IPLEX(TM) in the ROP indication during the second quarter of 2009.
  • "The sale of our FOB assets to Merck represents a watershed moment for Insmed," said Dr. Geoffrey Allan, Ph.D., President and CEO Insmed. "This agreement demonstrates Insmed's world-class clinical capabilities, and provides us with a substantial cash infusion that positions us well for future growth. In the short-term, we expect to be cash neutral for the balance of 2009 as we continue moving ahead with our IPLEX(TM) programs for MMD and ALS. In addition, we intend to pursue a comprehensive and thoughtful analysis to determine the most appropriate use of the proceeds we will receive from Merck. Our objective, though, is to utilize this capital to grow our business, and create additional shareholder value, as we have done through the transaction with Merck."

    Financial Results for Fourth Quarter and Full-year 2008

    Revenues for the fourth quarter ended December 31, 2008 were $2.9 million, up from $2.1 for the corresponding period in 2007. The increase was mainly attributable to an $846,000 increase in cost recovery revenue from our EAP to treat patients with ALS in Italy.

    The net loss for the fourth quarter of 2008 was $4.0 million or $0.03 per share, compared with a net loss of $3.3 million or $0.03 per share in the fourth quarter of 2007.

    R&D expenses increased to $5.4 million from $4.6 million, reflecting an increase in clinical trial activity for our FOB and IPLEX(TM) programs. SG&A Expenses increased to $1.3 million from $0.9 million, du
    '/>"/>

    SOURCE Insmed Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
    2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
    3. Insmed to Appeal Delisting Notification From Nasdaq
    4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
    5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
    6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
    7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
    8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
    9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
    10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
    11. Insmed to Present at CBI Follow-On Biologics Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2015)... , August 27, 2015 GlassesOff ... image processing functions in the human vision system, announced today ... point guard Chris Paul to develop a ... who want to improve their real-life on-court performance. ... court, whether it is shooting a ball or blocking a ...
    (Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... customers’ weighing needs and expertly narrows down the product choices to a manageable ... criteria pares down the list to models that fit best with the customer’s ...
    (Date:8/27/2015)... Irvine, CA (PRWEB) , ... August 27, 2015 ... ... leader in Personalized Medicine, recently presented new data on the relationship of genetics ... 2015 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The ...
    (Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
    Breaking Biology Technology:Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3METTLER TOLEDO Updates Online Scale Selection Tool 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3
    ... April 23 Government and private insurers are placing ... for the products they develop, according to The 2009 ... governments and individuals are likely to increase demands to ... mounting healthcare costs, a shrinking tax base, aging populations, ...
    ... /PRNewswire-Asia-FirstCall/ --, - Fourth Quarter 2008 Revenue Increased 28.6% to ... and Diluted EPS of $.03, - 2008 Revenues Increased 23.5% ... Improved 340 Basis Points to 20.1%, - 2008 Net Income ... $0.13, - 2008 Cash Flow from Operations was $5.9 ...
    ... 2009 came to a close were forced to announce layoffs, and the U.S. ... rest of the country as job creation for March contracted by 50 percent. ... ... came to a close in March, several companies announced layoffs, and while many ...
    Cached Biology Technology:Failing to Demonstrate Value of Innovation is Top Risk Facing Life Sciences Sector, According to Ernst & Young 2Failing to Demonstrate Value of Innovation is Top Risk Facing Life Sciences Sector, According to Ernst & Young 3Failing to Demonstrate Value of Innovation is Top Risk Facing Life Sciences Sector, According to Ernst & Young 4China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 2China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 3China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 4China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 5China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 6China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 7China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 8China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 9China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 10China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results 11The MedZilla Report: March 2009 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: March 2009 Employment Outlook for Biotech/Pharma/Health 3The MedZilla Report: March 2009 Employment Outlook for Biotech/Pharma/Health 4
    (Date:8/5/2015)... VIEW, Calif. , Aug. 5, 2015 ... exhibits continuous growth in applications, penetration into newer sectors, ... after year. The global biosensors space has seen the ... exited the market so far. (Photo - ... Frost & Sullivan, Analysis of the Global Biosensors ...
    (Date:7/31/2015)... , 31 de julio de 2015 ... (ICG-10,  www.icg-10.org ) del 22 al 25 de octubre ... La conferencia celebra su décimo aniversario este ... convertido en una de las reuniones anuales más influyentes ... es una de las conferencias científicas más dinámicas, entusiastas ...
    (Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
    Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
    ... the Appalachian Mountains is a tiger swallowtail butterfly that ... ago. It,s a rarity in the animal world, ... tiger swallowtail, Papilio appalachiensis, evolved from mixing between the ... and the Canadian tiger swallowtail, P. canadensis . ...
    ... HOUSTON -- Gene therapy delivered directly to a particularly ... to self-destruct, lowers chance of recurrence and helps increase ... The University of Texas MD Anderson Cancer Center reported ... . In cellular and mouse studies, scientists found ...
    ... 12, 2011A study presented today by Universit Laval researchers at ... Quebec City revealed that the risk of insomnia is 67% ... member is an insomniac. The research team, directed ... Psychology, came to these conclusions following a study involving 3,485 ...
    Cached Biology News:A tale of (more than) 2 butterflies 2A tale of (more than) 2 butterflies 3Gene therapy kills breast cancer stem cells, boosts chemotherapy 2Gene therapy kills breast cancer stem cells, boosts chemotherapy 3
    Recognizes Kir4.1. The epitope does not share homology with any other known proteins.,SPECIES REACTIVITIES: The antibody is also expected to work with mouse and human due to sequence homology. Oth...
    Evi-1 Antibody Shipping Temperature: Cold Storage Temperature: -20C...
    Profilin-1/2 (FL-140)...
    Immunogen: Synthetic peptide: N(171) H G F L S A D Q QL I K(183) Storage: -20 C, Avoid Freeze/Thaw Cycles...
    Biology Products: